Condition: Myelofibrosis · Sponsor: Memorial Sloan Kettering Cancer Center
The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis. The researchers will test different doses of ulixertinib to find the highest dose that causes few or mild side effects in participants when given in combination with ruxolitinib.
This description comes directly from the study's public registry record.
Raajit Rampal, MD, PhD · 646-608-3746 · rampalr@mskcc.org
Prioty Islam, MD, MS · 646-608-4273
Always discuss trial participation with your own doctor first.
| Massachusetts General Hospital (Data Collection Only) | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale, New York, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06773195